Pharmafile Logo
Pharmafocus logo
Advanced Search

Eisai

Showing 15 posts of 111 posts found.

Eisai image

Eisai opens Fycompa UK manufacturing line

September 25, 2012
Manufacturing and Production, Sales and Marketing Eisai, Fycompa

Eisai has opened a new solid dose production line for epilepsy drug Fycompa at its UK base in Hatfield, Hertfordshire. …

News
Halaven image

UK at centre of Eisai plans

September 18, 2012
Research and Development, Sales and Marketing CNS, Cancer Drugs Fund, Eisai, Fycompa, Halaven

Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as …

News
Eisai image

Eisai launches epilepsy drug in UK

September 14, 2012
Sales and Marketing Eisai, UK, epilepsy

Eisai has launched its first-in-class epilepsy drug Fycompa in the UK, prior to a roll-out in EU member states including …

News
FDA image

FDA clears Arena and Eisai’s obesity drug

June 28, 2012
Sales and Marketing Arena, Belviq, Eisai, FDA, Qnexa, Roche, obesity

Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …

News

Eisai to enter Russia with epilepsy launch

June 27, 2012
Sales and Marketing Eisai, Russia, Zonegran, emerging markets, epilepsy

Eisai is to enter the Russian market for the first time with the launch of epilepsy drug Zonegran. Entry into the …

News

Recommendations for two Eisai epilepsy drugs

May 28, 2012
Sales and Marketing CHMP, Eisai, Zonegra, epilepsy

European regulators are likely to approve two of Eisai’s epilepsy drugs after advisers recommended both of them.First-in-class Fycompa (perampanel) has …

News
FDA picture

Obesity drugs vie for approval as FDA panel backs lorcaserin

May 14, 2012
Research and Development, Sales and Marketing Arena, Eisai, FDA, Qnexa, lorcaserin, obesity

An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …

News
Halaven image

NICE rejects Halaven for breast cancer

April 3, 2012
Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs.  In its final …

News
Eisai logo

Eisai expands UK base

March 21, 2012
Sales and Marketing EMEA, Eisai, Hatfield, expansion

Eisai is expanding its UK headquarters to support the company’s growing European, Middle Eastern and African business. The expansion will …

News

Takeda’s blood pressure treatment Edarbi approved

December 9, 2011
Sales and Marketing Diovan, Eisai, cardiovascular, high blood pressure, hypertension

Takeda’s new hypertension treatment Edarbi has been approved in Europe.Edarbi (azilsartan medoxomil) is a new once-daily angiotensin receptor blocker (ARB) …

News

NICE will not back Eisai’s Halaven

November 17, 2011
Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …

News

Eisai shares risk with novel trial funding approach

September 7, 2011
Research and Development Eisai, clinical trials, research and development news

Eisai has unveiled a novel risk-sharing approach to accelerate its late-stage research programme by accepting new sources of clinical trial …

News

Zonegran study could pave way for paediatric licence

September 2, 2011
Research and Development, Sales and Marketing Eisai, Zonegran, epilepsy, research and development news

Eisai’s epilepsy drug Zonegran has been found more effective than placebo in children with the neurological condition who have seizures. …

News
FDA building

FDA refuses to file Eisai’s epilepsy drug

August 1, 2011
Sales and Marketing Eisai, FDA, epilepsy

The FDA has refused to file Eisai’s epilepsy drug perampanel, saying it needs more information for the treatment. The FDA …

News

NICE says no to breast cancer treatment Halaven

July 20, 2011
Sales and Marketing Eisai, Halaven, NICE

Eisai’s Halaven has been rejected by NICE in draft guidance for locally advanced or metastatic breast cancer. Halaven (eribulin) is …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023